By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New York, Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.
The findings were published online today in JAMA Psychiatry.
In the past two decades, the pharmaceutical industry has spent over $2.5 billion to develop new schizophrenia drugs. But while many appear to be effective in animal models, most fail when tested in late-stage human clinical trials.
“While a great deal of money has been invested in developing schizophrenia drugs, a similar investment hasn’t …
https://www.newsrx.com/Butter/#!Search:a=14802737
(2017-12-04), Schizophrenia drug development may be ‘de-risked’ with new research tool, Mental Health Weekly Digest, 303, ISSN: 1543-6608, BUTTER® ID: 014802737